Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT6EC79B)

• DOT Name: Ribonuclease inhibitor (RNH1)
• Synonyms: Placental ribonuclease inhibitor; Placental RNase inhibitor; Ribonuclease/angiogenin inhibitor 1; RAI
• Gene Name: RNH1
• Related Disease:
  Differentiated thyroid carcinoma
  Non-insulin dependent diabetes
  Parkinson disease
  Adenoma
  Advanced cancer
  Breast cancer
  Breast carcinoma
  Carcinoma
  Colorectal adenoma
  Complete hydatidiform mole
  Depression
  Epithelial ovarian cancer
  Gastric cancer
  Graves disease
  Hairy cell leukaemia
  HIV infectious disease
  Liver cirrhosis
  Lung cancer
  Lung carcinoma
  Medullary thyroid gland carcinoma
  Plasma cell myeloma
  Pulmonary fibrosis
  Schizophrenia
  Small lymphocytic lymphoma
  Smith-Magenis syndrome
  Stomach cancer
  Testicular cancer
  Cervical carcinoma
  Melanoma
  Metastatic malignant neoplasm
  Thyroid gland papillary carcinoma
  Thyrotoxicosis
  Cerebral infarction
  Neuroblastoma
  Bladder cancer
  Bone osteosarcoma
  Helicoid peripapillary chorioretinal degeneration
  Hepatitis C virus infection
  Neoplasm
  Osteosarcoma
  Thyroid gland undifferentiated (anaplastic) carcinoma
  Urinary bladder cancer
  Urinary bladder neoplasm
• UniProt ID: RINI_HUMAN
• PDB ID: 1A4Y; 1Z7X; 2BEX; 2Q4G
• Pfam ID: PF13516 ; PF18779
• Sequence:
  MSLDIQSLDIQCEELSDARWAELLPLLQQCQVVRLDDCGLTEARCKDISSALRVNPALAE
  LNLRSNELGDVGVHCVLQGLQTPSCKIQKLSLQNCCLTGAGCGVLSSTLRTLPTLQELHL
  SDNLLGDAGLQLLCEGLLDPQCRLEKLQLEYCSLSAASCEPLASVLRAKPDFKELTVSNN
  DINEAGVRVLCQGLKDSPCQLEALKLESCGVTSDNCRDLCGIVASKASLRELALGSNKLG
  DVGMAELCPGLLHPSSRLRTLWIWECGITAKGCGDLCRVLRAKESLKELSLAGNELGDEG
  ARLLCETLLEPGCQLESLWVKSCSFTAACCSHFSSVLAQNRFLLELQISNNRLEDAGVRE
  LCQGLGQPGSVLRVLWLADCDVSDSSCSSLAATLLANHSLRELDLSNNCLGDAGILQLVE
  SVRQPGCLLEQLVLYDIYWSEEMEDRLQALEKDKPSLRVIS
• Function: Ribonuclease inhibitor which inhibits RNASE1, RNASE2 and ANG. May play a role in redox homeostasis.

Molecular Interaction Atlas (MIA) of This DOT

43 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Differentiated thyroid carcinoma	DIS1V20Y	Definitive	Biomarker	[1]
Non-insulin dependent diabetes	DISK1O5Z	Definitive	Biomarker	[2]
Parkinson disease	DISQVHKL	Definitive	Biomarker	[3]
Adenoma	DIS78ZEV	Strong	Genetic Variation	[4]
Advanced cancer	DISAT1Z9	Strong	Biomarker	[5]
Breast cancer	DIS7DPX1	Strong	Genetic Variation	[6]
Breast carcinoma	DIS2UE88	Strong	Genetic Variation	[6]
Carcinoma	DISH9F1N	Strong	Genetic Variation	[4]
Colorectal adenoma	DISTSVHM	Strong	Biomarker	[4]
Complete hydatidiform mole	DIS5QPI0	Strong	Altered Expression	[7]
Depression	DIS3XJ69	Strong	Biomarker	[8]
Epithelial ovarian cancer	DIS56MH2	Strong	Biomarker	[9]
Gastric cancer	DISXGOUK	Strong	Biomarker	[10]
Graves disease	DISU4KOQ	Strong	Biomarker	[11]
Hairy cell leukaemia	DISTD2E5	Strong	Biomarker	[12]
HIV infectious disease	DISO97HC	Strong	Biomarker	[13]
Liver cirrhosis	DIS4G1GX	Strong	Biomarker	[14]
Lung cancer	DISCM4YA	Strong	Genetic Variation	[6]
Lung carcinoma	DISTR26C	Strong	Genetic Variation	[6]
Medullary thyroid gland carcinoma	DISHBL3K	Strong	Genetic Variation	[15]
Plasma cell myeloma	DIS0DFZ0	Strong	Genetic Variation	[16]
Pulmonary fibrosis	DISQKVLA	Strong	Biomarker	[17]
Schizophrenia	DISSRV2N	Strong	Altered Expression	[18]
Small lymphocytic lymphoma	DIS30POX	Strong	Altered Expression	[19]
Smith-Magenis syndrome	DISG4G6X	Strong	Genetic Variation	[20]
Stomach cancer	DISKIJSX	Strong	Biomarker	[10]
Testicular cancer	DIS6HNYO	Strong	Genetic Variation	[21]
Cervical carcinoma	DIST4S00	moderate	Biomarker	[22]
Melanoma	DIS1RRCY	moderate	Biomarker	[23]
Metastatic malignant neoplasm	DIS86UK6	moderate	Biomarker	[1]
Thyroid gland papillary carcinoma	DIS48YMM	moderate	Biomarker	[24]
Thyrotoxicosis	DISWH7BV	moderate	Biomarker	[25]
Cerebral infarction	DISR1WNP	Disputed	Biomarker	[26]
Neuroblastoma	DISVZBI4	Disputed	Biomarker	[26]
Bladder cancer	DISUHNM0	Limited	Altered Expression	[27]
Bone osteosarcoma	DIST1004	Limited	Biomarker	[28]
Helicoid peripapillary chorioretinal degeneration	DISFSS5N	Limited	Biomarker	[29]
Hepatitis C virus infection	DISQ0M8R	Limited	Biomarker	[30]
Neoplasm	DISZKGEW	Limited	Genetic Variation	[29]
Osteosarcoma	DISLQ7E2	Limited	Biomarker	[28]
Thyroid gland undifferentiated (anaplastic) carcinoma	DISYBB1W	Limited	Genetic Variation	[31]
Urinary bladder cancer	DISDV4T7	Limited	Altered Expression	[27]
Urinary bladder neoplasm	DIS7HACE	Limited	Altered Expression	[27]

10 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the expression of Ribonuclease inhibitor (RNH1).	[32]
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Ribonuclease inhibitor (RNH1).	[33]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of Ribonuclease inhibitor (RNH1).	[34]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Ribonuclease inhibitor (RNH1).	[35]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide decreases the expression of Ribonuclease inhibitor (RNH1).	[36]
Selenium	DM25CGV	Approved	Selenium increases the expression of Ribonuclease inhibitor (RNH1).	[38]
Epigallocatechin gallate	DMCGWBJ	Phase 3	Epigallocatechin gallate decreases the expression of Ribonuclease inhibitor (RNH1).	[39]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 decreases the expression of Ribonuclease inhibitor (RNH1).	[39]
Phencyclidine	DMQBEYX	Investigative	Phencyclidine decreases the expression of Ribonuclease inhibitor (RNH1).	[43]
	DM9CEI5		increases the expression of Ribonuclease inhibitor (RNH1).	[44]

4 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Triclosan	DMZUR4N	Approved	Triclosan increases the methylation of Ribonuclease inhibitor (RNH1).	[37]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Ribonuclease inhibitor (RNH1).	[40]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the methylation of Ribonuclease inhibitor (RNH1).	[41]
Coumarin	DM0N8ZM	Investigative	Coumarin decreases the phosphorylation of Ribonuclease inhibitor (RNH1).	[42]

References

• [1] LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.Endocr Pract. 2019 May;25(5):427-437. doi: 10.4158/EP-2018-0465. Epub 2019 Jan 18.
• [2] Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.Endocr Pract. 2018 Sep;24(9):805-814. doi: 10.4158/EP-2017-0261. Epub 2018 Jul 5.
• [3] Comparison Between Automatic and Visual Scorings of REM Sleep Without Atonia for the Diagnosis of REM Sleep Behavior Disorder in Parkinson Disease.Sleep. 2017 Feb 1;40(2). doi: 10.1093/sleep/zsw060.
• [4] Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study.BMC Cancer. 2006 Jul 3;6:175. doi: 10.1186/1471-2407-6-175.
• [5] A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells.Mol Cancer Ther. 2018 Dec;17(12):2622-2632. doi: 10.1158/1535-7163.MCT-18-0724. Epub 2018 Oct 3.
• [6] A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study.BMC Cancer. 2008 Feb 20;8:54. doi: 10.1186/1471-2407-8-54.
• [7] Use of a novel system for defining a gene imprinting region.Biochem Biophys Res Commun. 1993 Oct 29;196(2):659-64. doi: 10.1006/bbrc.1993.2300.
• [8] Pain perception in patients with hidradenitis suppurativa.Br J Dermatol. 2020 Jan;182(1):166-174. doi: 10.1111/bjd.17935. Epub 2019 Jul 8.
• [9] Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/-catenin/CBP signaling.Clin Cancer Res. 2019 Feb 1;25(3):1022-1035. doi: 10.1158/1078-0432.CCR-18-2554. Epub 2018 Oct 2.
• [10] RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.Oncogene. 2014 Mar 20;33(12):1527-37. doi: 10.1038/onc.2013.104. Epub 2013 Apr 15.
• [11] Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.J Endocrinol Invest. 2020 Feb;43(2):219-229. doi: 10.1007/s40618-019-01105-7. Epub 2019 Aug 26.
• [12] Expression of CD45 isoforms in chronic B-cell leukaemias.Leuk Res. 1993 Mar;17(3):209-16. doi: 10.1016/0145-2126(93)90003-4.
• [13] Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.Curr HIV Res. 2007 Jul;5(4):430-9. doi: 10.2174/157016207781024009.
• [14] Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.EBioMedicine. 2017 Sep;23:79-87. doi: 10.1016/j.ebiom.2017.08.016. Epub 2017 Aug 19.
• [15] Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.J Clin Endocrinol Metab. 2019 Mar 1;104(3):779-784. doi: 10.1210/jc.2018-01836.
• [16] The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.Ann Hematol. 2011 Jun;90(6):675-84. doi: 10.1007/s00277-010-1105-z. Epub 2010 Nov 3.
• [17] The novel inhibitor PRI-724 for Wnt/-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice.Exp Lung Res. 2019 Sep;45(7):188-199. doi: 10.1080/01902148.2019.1638466. Epub 2019 Jul 12.
• [18] Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.J Neural Transm (Vienna). 2009 Mar;116(3):275-89. doi: 10.1007/s00702-008-0156-y. Epub 2008 Nov 26.
• [19] CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival.Int J Lab Hematol. 2017 Oct;39(5):552-556. doi: 10.1111/ijlh.12695. Epub 2017 Jun 12.
• [20] First evidence of Smith-Magenis syndrome in mother and daughter due to a novel RAI mutation.Am J Med Genet A. 2017 Jan;173(1):231-238. doi: 10.1002/ajmg.a.37989. Epub 2016 Sep 28.
• [21] Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer.Cancer Lett. 2005 Jul 28;225(2):245-51. doi: 10.1016/j.canlet.2005.03.021.
• [22] Differential tissue-specific protein markers of vaginal carcinoma.Br J Cancer. 2009 Apr 21;100(8):1303-14. doi: 10.1038/sj.bjc.6604975. Epub 2009 Mar 24.
• [23] Ribonuclease inhibitor up-regulation inhibits the growth and induces apoptosis in murine melanoma cells through repression of angiogenin and ILK/PI3K/AKT signaling pathway.Biochimie. 2014 Aug;103:89-100. doi: 10.1016/j.biochi.2014.04.007. Epub 2014 Apr 24.
• [24] BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer.Horm Metab Res. 2019 Jan;51(1):69-75. doi: 10.1055/a-0765-9078. Epub 2018 Nov 5.
• [25] Thyroid cancer post radioactive iodine treatment for hyperthyroidism - case series and review of the literature.Endokrynol Pol. 2017;68(5):561-566. doi: 10.5603/EP.a2017.0037. Epub 2017 Jun 6.
• [26] The Shc protein RAI promotes an adaptive cell survival program in hypoxic neuroblastoma cells.J Cell Physiol. 2018 May;233(5):4282-4293. doi: 10.1002/jcp.26247. Epub 2017 Nov 24.
• [27] Overexpression of ribonuclease inhibitor induces autophagy in human colorectal cancer cells via the Akt/mTOR/ULK1 pathway.Mol Med Rep. 2019 May;19(5):3519-3526. doi: 10.3892/mmr.2019.10030. Epub 2019 Mar 14.
• [28] Targeting the Wnt/-catenin pathway in human osteosarcoma cells.Oncotarget. 2018 Dec 4;9(95):36780-36792. doi: 10.18632/oncotarget.26377. eCollection 2018 Dec 4.
• [29] Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.Thyroid. 2019 Apr;29(4):530-539. doi: 10.1089/thy.2018.0687. Epub 2019 Feb 13.
• [30] Selective inhibitor of Wnt/-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model.Sci Rep. 2017 Mar 23;7(1):325. doi: 10.1038/s41598-017-00282-w.
• [31] Targeted Therapy in Thyroid Cancer: State of the Art.Clin Oncol (R Coll Radiol). 2017 May;29(5):316-324. doi: 10.1016/j.clon.2017.02.009. Epub 2017 Mar 17.
• [32] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [33] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [34] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [35] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [36] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [37] Pregnancy exposure to synthetic phenols and placental DNA methylation - An epigenome-wide association study in male infants from the EDEN cohort. Environ Pollut. 2021 Dec 1;290:118024. doi: 10.1016/j.envpol.2021.118024. Epub 2021 Aug 21.
• [38] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [39] Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.
• [40] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [41] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [42] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [43] Differential response of Mono Mac 6, BEAS-2B, and Jurkat cells to indoor dust. Environ Health Perspect. 2007 Sep;115(9):1325-32.
• [44] A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 2011 Jan 15;71(2):473-83. doi: 10.1158/0008-5472.CAN-10-1303. Epub 2011 Jan 11.